Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice.
We explored the specific impact of polyol pathway hyperactivity on dorsal root ganglia (DRG) using transgenic mice that overexpress human aldose reductase because DRG changes are crucial for the development of diabetic sensory neuropathy. Littermate mice served as controls. Half of the animals were made diabetic by streptozotocin injection and followed for 12 weeks. After diabetes onset, diabetic transgenic mice showed a significant elevation of pain sensation threshold after transient decrease and marked slowing of motor and sensory nerve conduction at the end of the study, while these changes were modest in diabetic littermate mice. Protein kinase C (PKC) activities were markedly reduced in diabetic transgenic mice, and the changes were associated with reduced expression of membrane PKC-alpha isoform that was translocated to cytosol. Membrane PKC-betaII isoform expression was contrariwise increased. Calcitonin gene-related peptide-and substance P-positive neurons were reduced in diabetic transgenic mice and less severely so in diabetic littermate mice. Morphometric analysis disclosed neuronal atrophy only in diabetic transgenic mice. Treatment with an aldose reductase inhibitor (fidarestat 4 mg x kg(-1) x day(-1), orally) corrected all of the changes detected in diabetic transgenic mice. These findings underscore the pathogenic role of aldose reductase in diabetic sensory neuropathy through the altered cellular signaling and peptide expressions in DRG neurons.
Uehara
Kenji
K
Department of Pathology, Hirosaki University School of Medicine, Hirosaki, Japan.
Yamagishi
Shin-Ichiro
S
Otsuki
Saori
S
Chin
Shyunsuke
S
Yagihashi
Soroku
S
D000199:Actins / Q000378:metabolism; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000473:pathology / Q000503:physiopathology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005727:Ganglia, Spinal / Q000473:pathology* / Q000503:physiopathology; D006801:Humans; D048289:Imidazolidines / Q000494:pharmacology; D007527:Isoenzymes / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009431:Neural Conduction / Q000502:physiology; D009474:Neurons / Q000473:pathology* / Q000502:physiology; D011493:Protein Kinase C / Q000378:metabolism*; D012016:Reference Values; D013373:Substance P / Q000378:metabolism
D000199:Actins; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D048289:Imidazolidines; D007527:Isoenzymes; D013373:Substance P; C077139:fidarestat; D000449:Aldehyde Reductase; D011493:Protein Kinase C; D015740:Calcitonin Gene-Related Peptide